Epigenetic modulation of BDNF gene in patients with major depressive disorder by C. D&apos et al.
CORRESPONDENCE
t
m
w
c
i
p
e
P
i
t
S
m
a
t
i
m
a
d
e
k
e
d
r
t
i
m
n
t
M
c
s
i
c
a
*
p
g
R
T
C
cEpigenetic Modulation of BDNFGene in Patients with
Major Depressive Disorder
To the Editor:
Major depressive disorder (MDD) and bipolar disorder (BD)are prevalent and disabling mood disorders, character-ized by recurring mood fluctuations over the life span (1),
with potential overlapping genetic risk factors (2,3).
Brain-derived neurotrophic factor (BDNF), an important neu-
rotrophin influencing synaptic plasticity, has been extensively in-
vestigated as a plausible functional candidate gene underlying the
predisposition for developingmooddisorders (4,5), andDNAmeth-
ylation represents an epigenetic mechanism contributing to its
transcriptional regulation.
Recently, we observed selective alterations of BDNF gene tran-
scription in peripheral blood mononuclear cells (PBMCs) of BDII
versus BDI subjects andhealthy control subjects, on stable pharma-
cologic treatment, suggesting that DNA methylation at the gene
promoter is likely to play an important role in such changes (6). In
particular, we found a significant BDNF gene expression down-
regulation and, consistently, a hypermethylation of the BDNF
promoter region in BDII patients. Among the factors potentially
influencing methylation patterns, including, for instance, age,
phase of illness, diet, and trauma exposure, we suggested that
pharmacologic treatments might play a crucial role, in light of a
significant association in our study sample between reduced
methylation patterns and mood stabilizer treatment, particu-
larly lithium and valproic acid. Although this specific association
was more evident in BDI patients, mainly those treated with
mood stabilizers, BDII subjects, most of whom received a combi-
nation of mood stabilizers and antidepressants, showed hyper-
methylation of the BDNF promoter region.
To further investigate epigenetic mechanisms in mood disor-
ders and to better characterize the role of BDNF, we extended our
analysis to a group of patients with MDD (n  41) on stable phar-
macologic treatment, alongwith an age-matched group of healthy
control subjects (n 44).
The studywas conductedwith the appropriate ethical approval,
and all subjects provided written informed consent before enroll-
ment. Diagnoses were made by the administration of semistruc-
tured interviews based onDSM-IV criteria (Structured Clinical Inter-
view for DSM [SCID]-I and SCID-II) (7,8), and control subjects were
volunteers without any psychiatric disorder, as determined by the
nonpatient edition of the SCID (9). Preparation of nucleic acids,
analysis of BDNF gene expression, and DNA methylation at gene
promoter paralleled methods described in detail elsewhere (6).
A significant reduction of BDNF gene expression in MDD sub-
jects (.45 .10;p .05, according tounpaired t test) versus controls
(1.00 .21; Figure1A)wasobserved. In addition, an increaseofDNA
methylation at BDNF gene promoter was observed in MDD pa-
tients, compared with control subjects (32.52%  2.03% vs.
24.04% 2.08%; p .05, according to unpaired t test; Figure 1B).
When data were stratified on the basis of pharmacotherapy, pa-
tients on antidepressant drugs alone (i.e., selective serotonin and
selective norepinephrine reuptake inhibitors) showed a higher
level of DNA methylation of the BDNF promoter, compared with
patients receiving combination treatments of antidepressants plus
mood stabilizers (37.15%  3.32% vs. 27.14%  3.03%; p  .042,
according to unpaired t test; Figure 1C). When data were stratified
according tomood state (i.e., major depressive episode; euthymia),
no significant difference could be observed (Figure 1D). However,
depending on mood state, data stratification, taking into account
b
i
0006-3223/$36.00he pharmacotherapy, showed an even much higher level of DNA
ethylation of the BDNF promoter in depressed subjects treated
ith antidepressants (42.35  4.56), compared with patients re-
eiving additional mood stabilizers (27.73 3.63; p .02, accord-
ng to unpaired t test). No changes were observed in euthymic
atients (Figure 1E).
Taken as a whole, these findings seem to provide additional
vidence in relation to BDNF gene transcription reduction in the
BMCs of MDD patients, in accordance with previous observations
n BDII patients (6) and epigenetic regulation of BDNF transcription,
hus confirming its role as a potential biomarker inmood disorders.
pecific differences amongMDD subjects in BDNF gene regulation
ay depend, at least partially, on different treatment therapies, as
lready hypothesized for BD patients (6). Moreover, epigenetic al-
erations in MDDmay differentially occur during specific phases of
llness in patients on various pharmacologic treatments. Further-
ore, our findings seemto further confirmthatmoodstabilizers are
ssociatedwith reducedDNAmethylation of the BDNFpromoter in
epressed subjects comparedwith antidepressant drugs. The pres-
nce of such associations seems to indicate BDNF regulation as a
ey target for such drugs. It has already been suggested that the
valuation of BDNF levels may be a general biomarker of neuronal
ysfunction (particularly in BD) and that an effective treatmentmay
everse such alterations (10). The present findings document addi-
ional evidence for BDNF as a possible peripheral biological marker
n mood disorders, further stressing the relevance of epigenetic
echanisms in the pathophysiology of major psychoses (11). Fi-
ally, data on pharmacotherapy outline the different effects of an-
idepressants andmood stabilizers onDNAmethylation patterns in
DD, possibly depending on disease phase as well—another criti-
al issue with relevant clinical implications (12). Further compari-
ons across larger samples of unipolar and bipolar subjects, includ-
ng drug-free patients, in different illness phases are warranted to
onfirm these results.
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igure 1. Levels of brain-derived neurotrophic factor (BDNF) messenger
m)RNA in peripheral blood mononuclear cells (PBMCs) from patients diag-
osed with major depressive disorder (MDD). Box plots with whiskers from
inimumtomaximumrepresent 2-DDCt values calculatedby theDelta-Delta
t (DDCt) method. (A) Means of mRNA levels are expressed relative to
ontrol subjects. (B) Amount of methylated DNA in the promoter region of
DNF in PBMCs from both control and MDD subjects and from MDD pa-
ients alone (C) according to different therapies (mood stabilizers or antide-
ressant drugs), (D)mood state, or (E) both. Scatter plots with mean values
re shown. SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selec-
ive serotonin reuptake inhibitor.
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